See how AbbVie Inc. and Johnson & Johnson differ across market data and performance, so you can decide which asset best fits your strategy.
$254.49
NYSE
AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.
Johnson & Johnson is the world’s largest and most diversified healthcare company. Its operations are organized into two segments: Innovative Medicine and MedTech, which together account for all revenue following the 2023 separation of its consumer health business, Kenvue. After restructurings completed in 2023 and 2024, the pharmaceutical segment is focused on three core therapeutic areas: immunology, oncology, and neurology. From a geographic perspective, slightly more than half of the company’s total revenue comes from the United States.